Back to Search
Start Over
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
- Source :
- Multiple Sclerosis and Related Disorders
- Publication Year :
- 2020
- Publisher :
- Elsevier B.V., 2020.
-
Abstract
- Highlights • Ocrelizumab is not associated to increased severity in MS patients with COVID-19. • B-cell depleting treatment could impact on virus-specific antibody production. • B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation.<br />Background Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). Objectives to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. Methods Case series. Results Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. Conclusion Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
- Subjects :
- Male
Disease
0302 clinical medicine
Monoclonal
Pandemic
Disease modifying therapies
Viral
030212 general & internal medicine
Humanized
Clinical course
General Medicine
Middle Aged
Neurology
Female
Coronavirus Infections
medicine.drug
Adult
medicine.medical_specialty
Multiple Sclerosis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pneumonia, Viral
Clinical Neurology
Settore MED/26
Antibodies, Monoclonal, Humanized
Antibodies
Article
Betacoronavirus
Immunocompromised Host
03 medical and health sciences
Disease severity
Internal medicine
DMD
medicine
Humans
Immunologic Factors
Pandemics
IL-6
business.industry
Multiple sclerosis
DMT
COVID-19
Pneumonia
MS
medicine.disease
Settore MED/17
respiratory tract diseases
Ocrelizumab
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 22110356 and 22110348
- Volume :
- 45
- Database :
- OpenAIRE
- Journal :
- Multiple Sclerosis and Related Disorders
- Accession number :
- edsair.doi.dedup.....152e0915d1272ea5d822451c0aaaa738